Pulmonology

Cases and hospitalizations due to EV-D68, a rare form of enterovirus associated with acute flaccid myelitis (AFM), have been increasing among children across the country.

Respiratory symptoms are significant among individuals with a history of smoking tobacco even without airflow obstruction.

Novel insights into the risk-benefit profile of nintedanib in children and adolescents with fibrosing interstitial lung disease (ILD) were provided by late-breaking data presented at ERS 2022 regarding the InPedILD clinical trial.

Late-breaking data presented at ERS Congress 2022 show that inhaler sensors and mobile health (mHealth) applications combined with pharmacist counseling improved treatment adherence for patients with uncontrolled asthma.

These data support web-based self-management for individuals with COPD with an objective, clinically relevant, short-term increase in physical activity levels compared to usual care.

“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.

New cohort analysis suggest updates to broaden the age and smoking-rate eligibility may have benefitted the historic disparity in low-dose CT screening practice.

According to new research, stroke occurrence trends coinciding with tuberculous meningitis (TBM) are suggested to have regional characteristics.

Olipudase alfa (Xenpozyme) was developed by Sanofi to treat symptoms unrelated to the central nervous system in pediatric and adult patients with the life-threatening condition.

Severity of disease in patients with PAH coincided with cfDNA concentrations according to an NIH study with data from 2 independent cohorts.

Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F vaccine candidate demonstrated 85.7% efficacy in older patients with severe disease according to the phase 3 study.

A high calorie, high fat diet is needed for patients with cystic fibrosis (CF) to maintain a normal weight resulting in an emphasized focus on their nutrition and weight management.

The agency has taken new action against Juul while experts worry about youth addiction and health impacts. But the e-cigarette market has been already well established in the US.

New phase 3 ENHANCE-2 data support a potential submission by Verona Pharma to the FDA.

Reena Mehra, MD, MS, reviews telling signs, the role of obesity, and the importance of proper testing for sleep apnea.

The Cleveland Clinic Director of Sleep Disorders Research navigates the complexities of OSA presentation, progression, management and eradication with the Lungcast team.

Prior to the launch of FSR's webinar on pulmonary sarcoidosis, Mary McGowan, CEO, discusses the private listening session held with the FDA that addressed the critical needs in the field.

Though current use rates have declined since 2017, investigators believe more young adults are transitioning from experimental to habitual use.

Bronchiectasis varies in presentation and appears to affect individuals from broad areas of the country. According to Dr. Patrick Flume, the task is to figure out what the best method of management is.

The interventional pulmonology specialist discusses new technology and devices available for diagnosing lung cancer.

Field leader Carla Lamb, MD, discusses advances to evaluating and treating chronic diseases including lung cancer and COPD in this latest episode.

The issued marketing denial orders require the country's most popular vaping device company remove all commercial products on the basis of insufficient toxicity data.

The decision comes after the company announced positive phase 3 data for the combination vaccine candidate in adults aged 60 years and older.

A team of investigators observe notably improved health care cost savings among patients who initiated care more than a year prior to those who haven't at all.

Currently many more patients undergo right heart catheterization than is necessary for diagnosing pulmonary hypertension in patients with systemic sclerosis.